Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/jcbfm.2014.218 http://scihub22266oqcxt.onion/10.1038/jcbfm.2014.218 C4348386!4348386!25492113     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Cereb+Blood+Flow+Metab 2015 ; 35 (3): 348-58 Nephropedia Template TP {{tp|p=25492113|t=2015. Cannabinoids in experimental stroke: a systematic review and meta-analysis |pdf=|usr=}}{{25492113}} gab.com Text Cannabinoids in experimental stroke: a systematic review and meta-analysis JO: J Cereb Blood Flow Metab http://www.kidney.de/pget.php?&tw=1&pmid=25492113 #FOAvip Cannabinoids (CBs) show promise as neuroprotectants with some agents already licensed in humans for other conditions. We systematically reviewed CBs in preclinical stroke to guide further experimental protocols. We selected controlled studies assessing acute administration of CBs for experimental stroke, identified through systematic searches. Data were extracted on lesion volume, outcome and quality, and analyzed using random effect models. Results are expressed as standardized mean difference (SMD) with 95% confidence intervals (CIs). In all, 144 experiments (34 publications) assessed CBs on infarct volume in 1,473 animals. Cannabinoids reduced infarct volume in transient (SMD ?1.41 (95% CI ?1.71), ?1.11) P<0.00001) and permanent (?1.67 (?2.08, ?1.27), P<0.00001) ischemia and in all subclasses: endocannabinoids (?1.72 (?2.62, ?0.82), P=0.0002), CB1/CB2 ligands (?1.75 (?2.19, ?1.31), P<0.00001), CB2 ligands (?1.65 (?2.09, ?1.22), P<0.00001), cannabidiol (?1.20 (?1.63, ?0.77), P<0.00001), ?9-tetrahydrocannabinol (?1.43 (?2.01, ?0.86), P<0.00001), and HU-211 (?2.90 (?4.24, ?1.56), P<0.0001). Early and late neuroscores significantly improved with CB use (?1.27 (?1.58, ?0.95), P<0.00001; ?1.63 (?2.64, ?0.62), P<0.002 respectively) and there was no effect on survival. Statistical heterogeneity and publication bias was present, median study quality was 4 (range 1 to 6/8). Overall, CBs significantly reduced infarct volume and improve functional outcome in experimental stroke. Further studies in aged, female and larger animals, with other co-morbidities are required. Twit Text FOAVip Cannabinoids in experimental stroke: a systematic review and meta-analysis ????J Cereb Blood Flow Metab http://www.kidney.de/pget.php?&tw=1&pmid=25492113 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25492113 #FOAvip English Wikipedia <ref>{{Cite pmid|25492113}}</ref> Cannabinoids in experimental stroke: a systematic review and meta-analysis #MMPMID25492113 England TJ; Hind WH; Rasid NA; O'Sullivan SE J Cereb Blood Flow Metab 2015[Mar]; 35 (3): 348-58 PMID25492113show ga Cannabinoids (CBs) show promise as neuroprotectants with some agents already licensed in humans for other conditions. We systematically reviewed CBs in preclinical stroke to guide further experimental protocols. We selected controlled studies assessing acute administration of CBs for experimental stroke, identified through systematic searches. Data were extracted on lesion volume, outcome and quality, and analyzed using random effect models. Results are expressed as standardized mean difference (SMD) with 95% confidence intervals (CIs). In all, 144 experiments (34 publications) assessed CBs on infarct volume in 1,473 animals. Cannabinoids reduced infarct volume in transient (SMD ?1.41 (95% CI ?1.71), ?1.11) P<0.00001) and permanent (?1.67 (?2.08, ?1.27), P<0.00001) ischemia and in all subclasses: endocannabinoids (?1.72 (?2.62, ?0.82), P=0.0002), CB1/CB2 ligands (?1.75 (?2.19, ?1.31), P<0.00001), CB2 ligands (?1.65 (?2.09, ?1.22), P<0.00001), cannabidiol (?1.20 (?1.63, ?0.77), P<0.00001), ?9-tetrahydrocannabinol (?1.43 (?2.01, ?0.86), P<0.00001), and HU-211 (?2.90 (?4.24, ?1.56), P<0.0001). Early and late neuroscores significantly improved with CB use (?1.27 (?1.58, ?0.95), P<0.00001; ?1.63 (?2.64, ?0.62), P<0.002 respectively) and there was no effect on survival. Statistical heterogeneity and publication bias was present, median study quality was 4 (range 1 to 6/8). Overall, CBs significantly reduced infarct volume and improve functional outcome in experimental stroke. Further studies in aged, female and larger animals, with other co-morbidities are required. äCannabinoids in experimental stroke: a systematic review and meta-anal(epmc).pdf DeepDyve Pubget Overpricing